The Department of Haematology charter is to provide optimum patient care and as widely as possible, add to the knowledge of the aetiology and pathogenesis of the blood disorders that are treated within the clinic. Also to develop more effective treatments and to build upon the existing understanding of haematological disorders.

Senior physician Lars Kjeldsen has overall responsibility for the department along with senior nurse Pernille Welinder.

The haematological disorders treated include amongst others;
-non malignant blood deseases such as, anaemia and thrombocytopenia.
-malignant lymfoma
-multiple myeloma
-acute leukaemias as well as chronic lympho- and myeloproliferative disorders.

The department provides bone marrow transplantations both bone marrow from related and unrelated donors. We also provide high dose chemotherapy with stem cell support (the patient's own stem cells).

The department is split into 3 integrated units or clinics that each comprise of out-patients, day-care and ward units. Each department is managed by a leader team comprising of a specialist doctor, a department nurse and secretary.

Clinic I 4033/4034 (ward and outpatients) responsible for treatment of malignant lymphoma and multiple myeloma.
Clinic I management team:
Senior physician: John Myhre
Department nurse: Birgith Skovsgaard
Secretary: Henriette Spauenfeldt

Clinic II 4043 og 4044 (ward and outpatients) responsible for the treatment of allogenic and autologous bone marrow transplantation.
Clinic II management team:
Senior physician: Doris Hovgaard
Department nurse: Laila von der Maase (ward)
Department nurse: Maria Hartmann (out patient clinic)
Secretary: Vivi Ljungberg

Clinic III 5052/4054 (ward and outpatients) responsible for the treatment of acute leukaemia chronic myeloproliferative disorders, chronic lymphatic leukaemi along with non-malignant haematological disorders.
Clinic III management team:
Senior physician: Jesper Jurlander
Department nurse: Tina Lnther
Secretary: Tina Skov 

The following haematologists have responsibility for the treatment, treatment programs and consultancy for the haematological disorders.

-Malignant Lymphoma: Senior physician Peter Brown.
-Myeloma and other chronic lymphoproliferative diseases excluding CLL and malignant lymphoma: Senior physician  Peter Gimsing.

-Allogenic bone marrow transplantation: Senior physician: Henrik Sengeløv.
-Mini Transplantation: Senior physician Lars Vindeløv.
-High dose chemotherapy with stem cell support: Senior physician Christian Geisler.

-Acute Leukaemia: Senior physician Ove Juul Nielsen.
-Chronic myeloproliferative disorders: Senior physician Ole Weis Bjerrum.
-Myelodysplastic syndrom, aplastic anaemia, thrombocytopenia, benign haematology: Senior physician Lars Kjeldsen
-CLL: Senior physician Jesper Jurlander.

Research and Development
The clinic's research effort is focussed in the areas of:

-Quantifying of allergic reactions, immune system function, graft-versus-host sickness, graft-versus-leukaemia effect and minimal residual sickness.

-To undertake experimental research in autologous stem cell transplantation among these specifically, minimal residual disease and the function of cell-cycle aberrations with respect to the success of high dose therapy.

-To investigate cell and the molecular biology of CD5+B-cell malignancies. (B-cell chronic lymphatic leukaemia (CLL) and mantle cell lymphoma(MCL), especially the molecular regulation of cell cycles and apoptosis.

-Neutrophile granulocytic cell biology, focussing on the functional characteristics of 3 newly discovered proteins, hCAP-18, NGAL and Grancalcin.

-Regulation of gene transcription during myelopoiesis in normal and malignant cells.

-The clinical effect of high dose treatment and autologous stem cell transplantation in relation to leukaemia, malignant lymphoma and myeloma.

-Flow cytometric quantifying of activated thrombocytes in relation to chronic myeloproliferative diseases.Flow cytometric quantifying of circulating thrombocytes-leukocyte aggregations in relation to chronic myeloproliferative diseases. Quantifying of fribrosis and coagulation parameters in the same patient group.